Cedilla tops off series B with additional $25M to test drugs in mesothelioma, certain breast cancers
Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials. The financing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Aspiring to understand and exploit protein stability, Cedilla Therapeutics has launched with $56.2 million in its first formal round of funding from Third Rock Ventures. Cambridge, Mass.-based Cedilla ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the ...
Adam Mars-Jones’s new novel represents a considerable advance on its predecessor, Pilcrow. Since that book was an extraordinary performance, we are clearly in the presence of a formidable talent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results